Inogen Q1 Revenue Up 3.4%, Enters US OSA Market

Inogen (Nasdaq: INGN) reported first quarter 2026 revenue of $85.1m on 7 May, up 3.4% year-on-year and ahead of company guidance. Growth was driven by international portable oxygen concentrator demand, which offset weaker US sales and rentals, while the company entered the obstructive sleep apnea market with the US launch of its Aurora CPAP mask range. Full-year guidance was reiterated at $366m to $373m.

The geographic mix tells the story. International sales rose 17.8% to $37.7m, or 5.9% in constant currency, while US sales fell 4.8% to $34.7m and US rentals were down 8.0% to $12.7m. Gross margin firmed to 44.5%, with adjusted gross margin up 30 basis points to 44.7%. GAAP net loss widened to $8.3m from $6.2m a year earlier, with adjusted EBITDA swinging to a $1.4m loss as R&D investment ramped.

Strategically, the quarter saw Inogen open a new front in obstructive sleep apnea with the US launch of FDA-cleared Aurora CPAP masks, with a 90-day in-home patient preference study accepted for presentation at SLEEP 2026 in Baltimore. The Rove 6 portable oxygen concentrator launched in Brazil, deepening Inogen’s international footprint, and the IMPACTS-200 trial began enrolling patients as the first US reimbursement study for the Simeox 200 airway clearance device.

The company also authorised a $30m share repurchase programme, having already deployed $1.9m on buybacks during the quarter. Inogen closed Q1 with $111.5m in cash and marketable securities, and no debt outstanding.

Inogen’s Q1 print is a portfolio diversification story dressed as an earnings beat. Domestic POC and rental softness is being papered over by international expansion and a strategic push into adjacent respiratory categories, particularly sleep apnea. Whether the H2 reacceleration management is forecasting materialises will depend on Aurora traction in the US OSA market and reimbursement progress for Simeox 200.